Evolution of Health Technology Assessment in Indonesia: Supply Landscape, Implementation, and Future Directions

被引:1
作者
Hidayat, Budi [1 ,2 ]
机构
[1] Univ Indonesia, Fac Publ Hlth, Ctr Hlth Econ & Policy Studies CHEPS, Depok, Indonesia
[2] Minist Hlth, Indonesian Hlth Technol Assessments Comm InaHTAC, Jakarta, Indonesia
关键词
Institutionalized health technology assessment; economics evaluation; priority-setting decision; Indonesia; benefit package; COST-EFFECTIVENESS; THRESHOLDS;
D O I
10.1080/23288604.2024.2371470
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
In 2014, Indonesia's Ministry of Health established the Indonesian Health Technology Assessment Committee (InaHTAC) to prioritize evidence-based health care technology for inclusion in the national health insurance benefits package. This commentary provides an overview of the current state of the health care technology supply landscape in Indonesia, as well as the impact of HTA studies on priority-setting decisions. Indonesia's decision-making process for health care technology approval and patient access involves multiple stakeholders and follows several evaluation principles. The licensing, inclusion, and evaluation of health care technology is complex and time consuming, however, requiring input from stakeholders with different roles and interests. Although efforts have been made to establish an HTA ecosystem by, for example, engaging in capacity-building activities and issuing guidelines, challenges remain, including a lack of infrastructure, financial resources, and technical capacity and inadequate stakeholder involvement. Additionally, the current position of the HTA unit, which is connected to the Ministry of Health (MOH), and political pressures from the pharmaceutical industry can result in delayed or ignored HTA recommendations. Therefore, the establishment of an independent and robust HTA body that can inform policy makers about health technology development, licensing, dissemination, and use, along with strong regulations to ensure harmonization and coordination among stakeholders, is necessary. This requires a step-by-step approach to address inadequate overall HTA resources.
引用
收藏
页数:10
相关论文
共 35 条
  • [1] [Anonymous], 2018, CNN Indonesia
  • [2] [Anonymous], 2024, Trastuzumab Masuk dalam Daftar Obat Kanker pada Fornas 2024
  • [3] [Anonymous], 2014, Keputusan Menteri Kesehatan
  • [4] [Anonymous], 2020, TNP2K
  • [5] [Anonymous], 2023, Keputusan Menteri Kesehatan 2197/2023 tentang Formularium Nasional
  • [6] [Anonymous], 2021, Situational analysis of health technology as the first step to develop HTA roadmap in Indonesia
  • [7] Cost-effectiveness thresholds: pros and cons
    Bertram, Melanie Y.
    Lauer, Jeremy A.
    De Joncheere, Kees
    Edejer, Tessa
    Hutubessy, Raymond
    Kieny, Marie-Paule
    Hill, Suzanne R.
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2016, 94 (12) : 925 - 930
  • [8] Health Technology Assessment: Global Advocacy and Local Realities Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness"
    Chalkidou, Kalipso
    Li, Ryan
    Culyer, Anthony J.
    Glassman, Amanda
    Hofman, Karen J.
    Teerawattananon, Yot
    [J]. INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2017, 6 (04) : 233 - 236
  • [9] Priority-setting for achieving universal health coverage
    Chalkidou, Kalipso
    Glassman, Amanda
    Marten, Robert
    Vega, Jeanette
    Teerawattananon, Yot
    Tritasavit, Nattha
    Gyansa-Lutterodt, Martha
    Seiter, Andreas
    Kieny, Marie Paule
    Hofman, Karen
    Culyer, Anthony J.
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2016, 94 (06) : 462 - 467
  • [10] Navigating HTA implementation: a review of Indonesia's revised HTA guideline
    Chavarina, Kinanti Khansa
    Faradiba, Dian
    Teerawattananon, Yot
    [J]. LANCET REGIONAL HEALTH - SOUTHEAST ASIA, 2023, 17